Monoclonal antibody · Immune activation, directed at CD30 (TNFRSF8) · developed by Xencor
XmAb2513 is a humanized monoclonal antibody that binds the CD30 receptor, a member of the tumor necrosis factor receptor superfamily expressed on certain lymphoma cells. It is being studied in Hodgkin lymphoma and anaplastic large cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00606645 | Phase 1 | Hodgkin Lymphoma | Completed | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Anaplastic Large Cell LymphomaHodgkin Lymphoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.
See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XNCR catalysts and pipeline →